High IgE serum levels and "peptic" ulcers: clinical and functional approach.
The prevalence of high total IgE serum levels was evaluated in 232 consecutive patients suffering from peptic ulcer. Twenty-one percent of the patients presented total IgE serum levels above 200 KU/L compared with the 5% found in a healthy control population (p < 0.004). Similar prevalence was found in gastric and/or duodenal ulcers. No significant differences in the duration of the disease, smoking habits, familiarity for peptic ulcer, symptomatology and frequency of complications were observed between patients with high and with normal total IgE serum levels. Gastric function studies (gastric acid secretion, serum pepsinogen and gastrin levels) did not show any significant differences between the two groups. The incidence of Helicobacter pylori infection was 65% in patients with normal IgE levels and 75% in those with high IgE levels (p: n.s.). The response to treatment with full dose of H2-receptor antagonists was comparable in both groups (91.25% and 90.7% of ulcer healing after 6-8 weeks of treatment). A relapse of the ulcer after 6 months of maintenance therapy (half dose of H2-receptor antagonists) was observed in 39.5% of the patients with ulcer and high total IgE serum as against the 11.9% observed in patients with normal IgE (p < 0.001). These data lend further support to the hypothesis of an underlying immuno-allergic reaction in some forms of gastric or duodenal ulcer.
De Lazzari
F
F
Divisione di Gastroenterologia, Istituto di Medicina Interna, Università degli Studi di Padova, Italy.
Mancin
O
O
Plebani
M
M
Venturi
C
C
Battaglia
G
G
Vianello
F
F
Galliani
E A
EA
Di Mario
F
F
Naccarato
R
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004381:Duodenal Ulcer / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D005512:Food Hypersensitivity / Q000150:complications; D005744:Gastric Acid / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D016481:Helicobacter Infections / Q000150:complications / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D015995:Prevalence; D011454:Prostaglandins A / Q000097:blood; D012008:Recurrence; D013276:Stomach Ulcer / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D016896:Treatment Outcome
D005755:Gastrins; D006635:Histamine H2 Antagonists; D011454:Prostaglandins A; D007073:Immunoglobulin E